StereoTactic radiotherapy for wet Age-Related macular degeneration (STAR): Study protocol for a randomised controlled clinical trial

Trials

Volumn 17, Issue 1, 2016, Pages

  Neffendorf, James E ^a,b   Desai, Riti ^a   Wang, Yanzhong ^c   Kelly, Joanna ^c   Murphy, Caroline ^c   Reeves, Barnaby C ^d   Chakravarthy, Usha ^e   Wordsworth, Sarah ^f   Lewis, Cornelius ^a   Peacock, Janet ^c   Uddin, Shahir ^a   O'Sullivan, Joe M ^e   Jackson, Timothy L ^a,b  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c KING'S COLLEGE LONDON   (United Kingdom)

^d UNIVERSITY OF BRISTOL   (United Kingdom)

^e QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^f UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Anti vascular endothelial growth factor; Neovascular age related macular degeneration; Radiation; Ranibizumab; STAR study; Stereotactic radiotherapy; VEGF; Wet age related macular degeneration

Indexed keywords

RANIBIZUMAB; ANGIOGENESIS INHIBITOR;

AGE RELATED MACULAR DEGENERATION; ARTICLE; CLINICAL PROTOCOL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; EXPERIMENTAL STUDY; HUMAN; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; MEDICAL DEVICE; MONOTHERAPY; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; QUALITY OF LIFE; RADIATION DOSE; RANDOMIZED CONTROLLED TRIAL; RETINOPATHY; SAFETY; SAMPLE SIZE; STEREOTACTIC BODY RADIATION THERAPY; TREATMENT OUTCOME; VISUAL ACUITY; CLINICAL TRIAL; CONVALESCENCE; DRUG ADMINISTRATION; INTRAVITREAL DRUG ADMINISTRATION; MACULAR DEGENERATION; METHODOLOGY; MULTIMODALITY CANCER THERAPY; PATHOPHYSIOLOGY; RADIOSURGERY; TIME FACTOR; UNITED KINGDOM; WET MACULAR DEGENERATION;

ANGIOGENESIS INHIBITORS; CLINICAL PROTOCOLS; COMBINED MODALITY THERAPY; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; HUMANS; INTENTION TO TREAT ANALYSIS; INTRAVITREAL INJECTIONS; MACULAR DEGENERATION; QUALITY OF LIFE; RADIOSURGERY; RANIBIZUMAB; RECOVERY OF FUNCTION; RESEARCH DESIGN; TIME FACTORS; TREATMENT OUTCOME; UNITED KINGDOM; VISUAL ACUITY; WET MACULAR DEGENERATION;

EID: 84997470976     PISSN: None     EISSN: 17456215     Source Type: Journal    
DOI: 10.1186/s13063-016-1676-7     Document Type: Article

References (26)

1. Klein R, Klein BE, Jensen SC, Mares-Perlman JA, Cruickshanks KJ, Palta M. Age-related maculopathy in a multiracial United States population: the National Health and Nutritional Examination Survey III. Ophthalmology. 1999;106(6):1056-65.
2. Owen CG, Jarrar Z, Wormald R, et al. The estimated prevalence and incidence of late stage age related macular degeneration in the UK. Br J Ophthalmol. 2012;96(5):752-6.
3. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1432-44.
4. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1419-31.
5. Amoaku WM, Chakravarthy U, Gale R, et al. Defining response to anti-VEGF therapies in neovascular AMD. Eye (Lond). 2015;29(6):721-31.
6. Miyamoto H, Kimura H, Yasukawa T, et al. Effect of focal X-ray irradiation on experimental choroidal neovascularization. Invest Ophthalmol Vis Sci. 1999;40(7):1496-502.
7. Chakravarthy U, Gardiner TA, Archer DB, Maguire CJ. A light microscopic and autoradiographic study of non-irradiated and irradiated ocular wounds. Curr Eye Res. 1989;8(4):337-48.
8. Aisenbrey S, Lafaut BA, Reynders S, et al. Clinicopathological correlation of choroidal neovascularization after external beam radiotherapy in age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2003;241(4):269-76.
9. Canton VM, Quiroz-Mercado H, Velez-Montoya R, et al. 16 Gy low-voltage x-ray irradiation with ranibizumab therapy for AMD: 6-month safety and functional outcomes. Ophthalmic Surg Lasers Imaging. 2011;42(6):468-73.
10. Canton VM, Quiroz-Mercado H, Velez-Montoya R, et al. 24-Gy low-voltage x-ray irradiation with ranibizumab therapy for neovascular AMD: 6-month safety and functional outcomes. Ophthalmic Surg Lasers Imaging. 2012;43(1):20-4.
11. Moshfeghi AA, Morales-Canton V, Quiroz-Mercado H, et al. 16 Gy low-voltage x-ray irradiation followed by as needed ranibizumab therapy for age-related macular degeneration: 12 month outcomes of a 'radiation-first' strategy. Br J Ophthalmol. 2012;96(10):1320-4.
12. Petrarca R, Jackson TL. Radiation therapy for neovascular age-related macular degeneration. Clin Ophthalmol. 2011;5:57-63.
13. Neffendorf JE, Jackson TL. Stereotactic radiotherapy for wet age-related macular degeneration: current perspectives. Clin Ophthalmol. 2015;9:1829-34.
14. Moshfeghi DM, Kaiser PK, Gertner M. Stereotactic low-voltage x-ray irradiation for age-related macular degeneration. Br J Ophthalmol. 2011;95(2):185-8.
15. Hanlon J, Firpo M, Chell E, et al. Stereotactic radiosurgery for AMD: a Monte-Carlo-based assessment of patient-specific tissue doses. Invest Ophthalmol Vis Sci. 2011;52(5):2334-42.
16. Jackson TL, Chakravarthy U, Kaiser PK, et al. Stereotactic radiotherapy for neovascular age-related macular degeneration: 52-week safety and efficacy results of the INTREPID study. Ophthalmology. 2013;120(9):1893-900.
17. Jackson TL, Chakravarthy U, Slakter JS, et al. Stereotactic radiotherapy for neovascular age-related macular degeneration: year 2 results of the INTREPID study. Ophthalmology. 2015;122(1):138-45.
18. Jackson TL, Shusterman EM, Arnoldussen M, Chell E, Wang K, Moshfeghi DM. Stereotactic radiotherapy for wet age-related macular degeneration (INTREPID): influence of baseline characteristics on clinical response. Retina. 2015;35(2):194-204.
19. Morales-Canton V, Quiroz-Mercado H, Velez-Montoya R, et al. 16 and 24 Gy Low-voltage x-ray irradiation with ranibizumab therapy for neovascular age-related macular degeneration: 12-month outcomes. Am J Ophthalmol. 2013;155(6):1000-8. e2.
20. Group CATT, Martin DF, Maguire MG, et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med. 2011;364(20):1897-908.
21. Mangione CM, Lee PP, Gutierrez PR, et al. Development of the 25-item National Eye Institute Visual Function Questionnaire. Arch Ophthalmol. 2001;119(7):1050-8.
22. The EuroQoL Group. EuroQoL-a new facility for the measurement of health-related quality of life. Health Policy. 1990;16(3):199-208.
23. Drummond MF, Sulpher MJ, Torrance GW, et al. Methods for the economic evaluation of health care programmes. 3rd ed. Oxford: Oxford University Press; 2005.
24. NICE. Guide to the methods of technology appraisal 2013. London: National Institute of Health and Care Excellence; 2013.
25. Investigators IS, Chakravarthy U, Harding SP, et al. Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial. Ophthalmology 2012;119(7):1399-411.
26. Velez-Montoya R, Oliver SCN, Olson JL, Fine SL, Quiroz-Mercado H, Mandava N. Current knowledge and trends in age-related macular degeneration. 2014;34(3):423-41.